2004-07-01
Restenosis rates following bifurcation stenting with sirolimus-eluting stents for de novo narrowings
Publication
Publication
The American Journal of Cardiology , Volume 94 - Issue 1 p. 115- 118
The percutaneous treatment of coronary bifurcation stenoses is hampered by an increased rate of subsequent restenosis. The present study reports on the outcomes of a consecutive series of 58 patients with 65 de novo bifurcation stenoses treated with sirolimus-eluting stent implantation in both the main vessel and side branch. At 6 months, the incidence of major adverse cardiac events was 10.3% (1 death and 5 target lesion revascularizations) with no episodes of acute myocardial infarction or stent thrombosis.
| Additional Metadata | |
|---|---|
| doi.org/10.1016/j.amjcard.2004.03.040, hdl.handle.net/1765/57443 | |
| The American Journal of Cardiology | |
| Organisation | Department of Cardiology |
|
Tanabe, K., Hoye, A., Lemos Neto, P., Aoki, J., Arampatzis, C., Saia, F., Lee, C. H., Degertekin, M., Hofma, S., Sianos, G., McFadden, E., Smits, P., van der Giessen, W., de Feyter, P., van Domburg, R.& Serruys, P. (2004). Restenosis rates following bifurcation stenting with sirolimus-eluting stents for de novo narrowings. The American Journal of Cardiology, 94(1), 115–118.https://doi.org/10.1016/j.amjcard.2004.03.040 |
|